Scarica l'app Stockscreener
1.63
16.84%
-0.33
Dopo l'orario di chiusura:
1.62
-0.010
-0.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Precedente Chiudi:
$1.96
Aprire:
$2
Volume 24 ore:
1.28M
Relative Volume:
2.81
Capitalizzazione di mercato:
$103.27M
Reddito:
$13.86M
Utile/perdita netta:
$-79.62M
Rapporto P/E:
-1.27
EPS:
-1.2835
Flusso di cassa netto:
$-63.51M
1 W Prestazione:
-14.66%
1M Prestazione:
-14.21%
6M Prestazione:
-69.13%
1 anno Prestazione:
+32.52%
Intervallo 1D:
$1.5717
$2.0431
Intervallo di 1 settimana:
$1.5717
$2.09
Portata 52W:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Nome
Pyxis Oncology Inc
Settore
Industria
Telefono
(617) 221-9059
Indirizzo
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.63 | 124.18M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2024-11-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-08-08 | Iniziato | Stifel | Buy |
| 2024-05-07 | Ripresa | Jefferies | Buy |
| 2024-02-09 | Iniziato | BTIG Research | Buy |
| 2024-01-23 | Iniziato | Leerink Partners | Outperform |
| 2023-09-05 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-02 | Iniziato | BofA Securities | Neutral |
| 2021-11-02 | Iniziato | Credit Suisse | Outperform |
| 2021-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo
RBC Capital Keeps Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail
Wedbush Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives - Sahm
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility - TipRanks
Pyxis Oncology, Inc. Faces Substantial Doubt as a Going Concern and Requires Additional Capital – 2026 Q1 Financial Report Highlights Risks and Challenges 25 - Minichart
Pyxis Oncology Shares Slide on Steeper 1Q Loss - Moomoo
Pyxis Oncology Reports Q1 2026 Financial Results and Advances MICVO ADC Toward Key Clinical Milestones in Head and Neck Cancer - Minichart
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS
Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan
Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - marketscreener.com
BRIEF-Pyxis Oncology Q1 Net Income USD -23.272 Million - TradingView
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Should You Sell Pyxis Oncology (PYXS) After -18.89% Drop? 2026-05-14Viral Trades - newser.com
Pyxis Oncology to Participate in Upcoming Investor Conferences - Caledonian Record
Cancer drug developer Pyxis Oncology plans investor webcasts - Stock Titan
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - MSN
Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - The Manila Times
SEC EDGAR Submission 0000950170-23-023950 - SEC.gov
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Pyxis Oncology, Inc. Appoints Nelson Azoulay as Chief Business Officer - marketscreener.com
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat
Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart
Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueDebt Analysis - newser.com
[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology | DEFA14A: Others - Moomoo
Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan
Pyxis Oncology | 8-K/A: Current report (Amendment) - Moomoo
Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan
Pyxis Oncology, Inc. Announces Resignation of Lara Sullivan from the Board of Directors, Effective April 29, 2026 - marketscreener.com
PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser
PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Community Driven Stock Picks - newser.com
PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget
Pyxis Oncology (PYXS) Cantor Global Healthcare Conference 2025 Summary - Quartr
Pyxis Oncology (PYXS) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Pyxis Oncology (PYXS) Registration Filing Summary - Quartr
Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr
Pyxis Oncology Inc Azioni (PYXS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):